This Website uses cookies. Learn more.

I understand. Hide this message.

Close

Close

MEDICAL RESOURCES

PrTEPMETKOTM (Tepotinib tablets)

Tablets

  • 225mg

Professed Standard Therapeutic Classification: Other Protein Kinase Inhibitors (L01EX21)

TEPMETKO has been issued marketing authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization.  For further information for TEPMETKO please refer to Health Canada’s Notice of Compliance with conditions - drug products web site

TEPMETKO is indicated for:

  • The treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations.

Product Labeling

Action SVG

REQUEST

INFORMATION

Click to submit your medical inquiry
Action SVG

REQUEST

CALL BACK

Click to schedule a time for us to call you back
Action SVG

REPORT

ADVERSE EVENT

Please call 1-888-737-6668 to report an adverse event